A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective
cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory
(R/R) hematologic malignancies. The purpose of this study is to evaluate the safety,
tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527.